Recent regulatory scrutiny in Germany has cast a spotlight on misoprostol (Angusta) and its role in labour induction, raising significant safety concerns. As this conversation unfolds across Europe, healthcare professionals are re-evaluating their induction protocols and looking to non-pharmacological methods like DILAPAN-S as a safer alternative.

Your Quarterly Update on Innovations in Women’s Health Welcome to the July 2025 edition of AGHeadlines , where we share the latest...

When a patient presents with abnormal uterine bleeding, particularly during or after menopause, one of the first concerns clinicians must...

carevix® significantly reduces pain and bleeding during transcervical procedures, including IUD insertions and more. Now available to clinics and patients in the UK.

Today, on the International Day of Action for Women’s Health , we stand in recognition and deep gratitude for the tireless work of...

In this edition: - The WID-easy test - New Evidence and Data - Upcoming Events - 4DryField PH Distributor Change